TY - JOUR
T1 - Cycloacceleration of ferroptosis and calcicoptosis for magnetic resonance imaging-guided colorectal cancer therapy
AU - Guo, Shuai
AU - Li, Zongheng
AU - Feng, Jie
AU - Xiong, Wei
AU - Yang, Jing
AU - Lu, Xuanyi
AU - Yang, Sugeun
AU - Xu, Yikai
AU - Wu, Aiguo
AU - Shen, Zheyu
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/12
Y1 - 2022/12
N2 - Ferroptosis therapy (FT) of the colorectal cancer (CRC) is usually restricted by the relatively slow rate of Fenton reaction due to the limited concentration of intracellular H2O2 and the high-level of endogenous H2S with strong reducibility. To develop an unprecedented strategy for precise targeted CRC theranostics, inspired by the “cyclotron” concept in physics, we propose a new concept of cycloacceleration of ferroptosis and calcicoptosis for the magnetic resonance imaging (MRI)-guided CRC therapy. The developed FGNPs@TA-Fe3/Ca4 nanoparticles have an ideal hydrodynamic diameter of 16.5 ± 2.2 nm and relatively high loading contents of Fe3+/Ca2+ (15.6 ± 3.4 % and 32.1 ± 1.9 %). The powerful T1 imaging ability of FGNPs@TA-Fe3/Ca4 with TME-responsive relaxivities is identified by 7.0 and 3.0 T of MRI scanners. The cycloacceleration of ferroptosis and calcicoptosis induced by FGNPs@TA-Fe3/Ca4 is reinforced by the MTT assay, and the measurements of reactive oxygen species (ROS), lipid peroxide (LPO), glutathione (GSH) peroxidase 4 (GPX4) bioactivity, GSH, H2S and SO2 of CT 26 cells with various treatments with or without ferroptosis or calcicoptosis inhibitors. The in vivo effectiveness and safety of FGNPs@TA-Fe3/Ca4 for MRI-guided CRC therapy based on cycloacceleration of ferroptosis and calcicoptosis are demonstrated on the CT 26 tumor-bearing BALB/c mice.
AB - Ferroptosis therapy (FT) of the colorectal cancer (CRC) is usually restricted by the relatively slow rate of Fenton reaction due to the limited concentration of intracellular H2O2 and the high-level of endogenous H2S with strong reducibility. To develop an unprecedented strategy for precise targeted CRC theranostics, inspired by the “cyclotron” concept in physics, we propose a new concept of cycloacceleration of ferroptosis and calcicoptosis for the magnetic resonance imaging (MRI)-guided CRC therapy. The developed FGNPs@TA-Fe3/Ca4 nanoparticles have an ideal hydrodynamic diameter of 16.5 ± 2.2 nm and relatively high loading contents of Fe3+/Ca2+ (15.6 ± 3.4 % and 32.1 ± 1.9 %). The powerful T1 imaging ability of FGNPs@TA-Fe3/Ca4 with TME-responsive relaxivities is identified by 7.0 and 3.0 T of MRI scanners. The cycloacceleration of ferroptosis and calcicoptosis induced by FGNPs@TA-Fe3/Ca4 is reinforced by the MTT assay, and the measurements of reactive oxygen species (ROS), lipid peroxide (LPO), glutathione (GSH) peroxidase 4 (GPX4) bioactivity, GSH, H2S and SO2 of CT 26 cells with various treatments with or without ferroptosis or calcicoptosis inhibitors. The in vivo effectiveness and safety of FGNPs@TA-Fe3/Ca4 for MRI-guided CRC therapy based on cycloacceleration of ferroptosis and calcicoptosis are demonstrated on the CT 26 tumor-bearing BALB/c mice.
KW - Calcicoptosis
KW - Colorectal cancer (CRC) therapy
KW - Cycloacceleration
KW - Ferroptosis
KW - Magnetic resonance imaging (MRI)
UR - http://www.scopus.com/inward/record.url?scp=85140977124&partnerID=8YFLogxK
U2 - 10.1016/j.nantod.2022.101663
DO - 10.1016/j.nantod.2022.101663
M3 - Article
AN - SCOPUS:85140977124
SN - 1748-0132
VL - 47
JO - Nano Today
JF - Nano Today
M1 - 101663
ER -